Announced receipt of up to 280,347 Canadian dollars in funding and advisory services from NRC IRAP to support development of a subcutaneous formulation of co-developed AV-001. Introduction of subcutaneous administration is expected to expand dosing options and enable earlier intervention.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4563","jir_company_name":"AnGes, Inc.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-10-06","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4563-20261006-01.pdf","jir_short_summary":"Announced receipt of up to 280,347 Canadian dollars in funding and advisory services from NRC IRAP to support development of a subcutaneous formulation of co-developed AV-001. Introduction of subcutaneous administration is expected to expand dosing options and enable earlier intervention.","jir_summary":"### News Summary\nAnGes, Inc. announced that it will receive up to 280,347 Canadian dollars in R&D funding and advisory services from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support development of a subcutaneous formulation of the Tie2 receptor agonist AV-001, being co-developed with Vasomune Therapeutics, Inc. The introduction of subcutaneous administration is positioned as an important step to broaden administration routes and timing options and to enable earlier intervention.\n\n### Background and Significance\nAdding subcutaneous administration could diversify dosing methods in addition to the current intravenous administration and may expand the applicability of treatments targeting vascular endothelial injury and vascular leakage. Utilization is anticipated in both civilian and military contexts, strengthening prevention and response through stabilization of the vascular endothelium via early intervention. Vasomune is advancing development of this therapeutic with dual-use applications in mind.","jir_financial_highlights":"Grant amount: Up to 280,347 Canadian dollars (approx. 31,500 thousand yen: exchange rate as of October 5) (Unknown)\nTarget therapeutic: Pegevongitide (AV-001) (Unknown)","jir_category":"","jir_hashtags":"#AnGes, #CoDevelopment, #IRNews","jir_key_figures":"Key figure 1: Up to 280,347 Canadian dollars (approx. 31,500 thousand yen)\nKey figure 2: Target drug AV-001 (Pegevongitide)\nKey figure 3: Period: Unknown (funding provided by NRC IRAP)","jir_meta_title":"AnGes: NRC IRAP Grant for Co-developed AV-001 Subcutaneous Formulation\uff5cOctober 2026","jir_meta_description":"AnGes and Vasomune announced receipt of up to 281 thousand Canadian dollars in grants and advisory support from NRC IRAP to advance the subcutaneous formulation of co-developed AV-001. The move is expected to expand administration options by introducing subcutaneous dosing.","jir_og_title":"AnGes: NRC IRAP Grant Awarded to Advance AV-001 Subcutaneous Formulation","jir_og_description":"Announced receipt of NRC IRAP funding to support development of AV-001 subcutaneous formulation. Introduction of subcutaneous dosing is expected to broaden administration options and enable earlier intervention for vascular endothelial injury treatments.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":57619,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"general_ir","footnotes":""},"sector":[],"importance":[],"class_list":["post-127624","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n